Javascript must be enabled to continue!
Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis
View through CrossRef
ObjectiveThe limitations of adrenocorticotrophic hormone (ACTH) treatment for infantile spasms (ISs), such as high costs, limited availability, and adverse effects (AEs), make it necessary to explore whether corticosteroids are optimal alternatives. Many other compelling treatments have gone through trials due to the suboptimal effectiveness of hormonal therapy. A systematic review and meta-analysis were performed to evaluate the effectiveness and safety of hormonal therapy for patients with ISs.MethodsEMBASE, Ovid MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and online registers were searched through April 2021 for randomized controlled trials (RCTs).ResultsA total of 19 RCTs (N = 1,279) were included. There was no significant difference in the effectiveness of oral corticosteroids and ACTH in electro-clinical response (risk ratio [RR] = 0.85, 95% CI 0.41–1.76). Low-dose ACTH had similar effectiveness in electro-clinical response compared to usual-dose group (RR = 0.94, 95% CI 0.60–1.47) but conferred a lower risk of AEs (RR = 1.71, 95% CI 1.08–2.71). ACTH was more beneficial in controlling spasms than vigabatrin (VGB) (RR = 1.31, 95% CI 1.05–1.64) for patients without tuberous sclerosis complex (TSC). All RCTs were connected through network meta-analysis, and we found that ketogenic diet (KD), zonisamide, methylprednisolone, or combined treatment of hormonal therapy with topiramate (TPM) or pyridoxine was not different in electro-clinical response compared to usual-dose ACTH.ConclusionOur analysis showed that oral corticosteroids could be optional alternatives when ACTH is not applicable, and ACTH is more beneficial for patients without TSC. Moreover, low-dose ACTH is recommended due to comparative effectiveness but lower risk of AEs. However, due to the high heterogeneity of included patients and treatment protocols, these results must be interpreted with caution. RCTs with multicentric involvement and larger sample size are needed for solid evaluation of other alternative treatments.
Frontiers Media SA
Title: Hormonal Therapy for Infantile Spasms: A Systematic Review and Meta-Analysis
Description:
ObjectiveThe limitations of adrenocorticotrophic hormone (ACTH) treatment for infantile spasms (ISs), such as high costs, limited availability, and adverse effects (AEs), make it necessary to explore whether corticosteroids are optimal alternatives.
Many other compelling treatments have gone through trials due to the suboptimal effectiveness of hormonal therapy.
A systematic review and meta-analysis were performed to evaluate the effectiveness and safety of hormonal therapy for patients with ISs.
MethodsEMBASE, Ovid MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and online registers were searched through April 2021 for randomized controlled trials (RCTs).
ResultsA total of 19 RCTs (N = 1,279) were included.
There was no significant difference in the effectiveness of oral corticosteroids and ACTH in electro-clinical response (risk ratio [RR] = 0.
85, 95% CI 0.
41–1.
76).
Low-dose ACTH had similar effectiveness in electro-clinical response compared to usual-dose group (RR = 0.
94, 95% CI 0.
60–1.
47) but conferred a lower risk of AEs (RR = 1.
71, 95% CI 1.
08–2.
71).
ACTH was more beneficial in controlling spasms than vigabatrin (VGB) (RR = 1.
31, 95% CI 1.
05–1.
64) for patients without tuberous sclerosis complex (TSC).
All RCTs were connected through network meta-analysis, and we found that ketogenic diet (KD), zonisamide, methylprednisolone, or combined treatment of hormonal therapy with topiramate (TPM) or pyridoxine was not different in electro-clinical response compared to usual-dose ACTH.
ConclusionOur analysis showed that oral corticosteroids could be optional alternatives when ACTH is not applicable, and ACTH is more beneficial for patients without TSC.
Moreover, low-dose ACTH is recommended due to comparative effectiveness but lower risk of AEs.
However, due to the high heterogeneity of included patients and treatment protocols, these results must be interpreted with caution.
RCTs with multicentric involvement and larger sample size are needed for solid evaluation of other alternative treatments.
Related Results
Infantile Spasms and Epilepsy Currents
Infantile Spasms and Epilepsy Currents
The United Kingdom Infantile Spasms Study Comparing Vigabatrin with Prednisolone or Tetracosactide at 14 Days: A Multicentre, Randomised Controlled Trial Lux AL, Edwards SW, Hanco...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Characteristics of malignant brain tumor‐associated epileptic spasms
Characteristics of malignant brain tumor‐associated epileptic spasms
AbstractAlthough epilepsy is the most common comorbidity of brain tumors, epileptic spasms rarely occur. Brain tumors associated with epileptic spasms are mostly low‐grade gliomas....
Benign spasms of infancy: a mimicker of infantile epileptic disorders*
Benign spasms of infancy: a mimicker of infantile epileptic disorders*
ABSTRACTBenign spasms of infancy (BSI), previously described as benign non‐epileptic infantile spasms or benign myoclonus of early infancy, are non‐epileptic movements manifesting ...
Vigabatrin versus ACTH in the treatment of infantile spasms
Vigabatrin versus ACTH in the treatment of infantile spasms
OBJECTIVE: To compare adrenocorticotropic hormone with vigabatrin as a single mono-therapy for infantile spasms. We studied hospitalization time, clinical response, whether complet...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
Do evidence summaries increase health policy‐makers' use of evidence from systematic reviews? A systematic review
This review summarizes the evidence from six randomized controlled trials that judged the effectiveness of systematic review summaries on policymakers' decision making, or the most...

